Immunohistochemistry vs Molecular Breast Cancer Subtyping Among African Populations
5 affiliations
- 1Aga Khan University Hospital, Nairobi, Kenya
- 2Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- 3AIC Kijabe Hospital, Kijabe, Kenya
- 4Mount Kenya University, Nairobi, Kenya
- 5Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
Abstract
Importance: Breast cancer subtyping based on immunohistochemistry (IHC) guides systemic therapy where gene expression profiling assays are unavailable, yet its validity against molecular reference standards remains poorly characterized in African populations, where laboratory infrastructure and access to pathology services are limited.
Objective: To evaluate concordance between IHC-based breast cancer subtyping and PAM50 intrinsic subtypes in East and West African populations and identify resource-appropriate strategies to improve classification.
Design, Setting, and Participants: This cross-sectional study included Kenyan (diagnosed 2012-2022) and Ghanaian women (diagnosed 2013-2015) with invasive breast cancer, from whom formalin-fixed, paraffin-embedded tumor specimens were collected during the same periods. Gene expression profiling and data analyses were performed between April 2020 and August 2026 for both cohorts.
Exposures: Tumor subtyping using standard IHC markers (estrogen receptor [ER], progesterone receptor [PR], and ERBB2 status and Ki-67) and histologic grade vs PAM50 intrinsic subtyping derived from a gene expression panel.
Main Outcomes and Measures: Concordance between IHC-based and PAM50 intrinsic subtypes was assessed using Cohen κ statistics, with sensitivity and specificity calculated against PAM50.
Results: Among 460 women in Kenya with breast cancer (mean [SD] age at diagnosis, 50.3 [12.5] years), 224 (49.4%) had grade 3 disease and 148 (42.3%) had stage III or IV tumors. A total of 451 women in Ghana with breast cancer (mean [SD] age, 49.9 [12.0] years; 317 [75.1%] with grade 3 disease) were enrolled as a validation cohort. PAM50 classified patients’ tumors as luminal A (201 tumors [43.7%]), luminal B (82 tumors [17.8%]), ERBB2 -enriched (50 tumors [10.9%]), basal-like (99 tumors [21.5%]), and normal-like (28 tumors [6.1%]). Concordance between IHC and PAM50 was highest for basal-like tumors (sensitivity ranging from 73.3% [95% CI, 61.9%-82.9%] to 79.6% [95% CI, 70.3%-87.1%]; specificity ranging from 96.9% [95% CI, 93.9%-98.6%] to 97.3% [95% CI, 94.9%-98.7%]) and moderate for ERBB2 -enriched tumors (sensitivity was 50.0% across all schemes, with 95% CIs ranging from 33.8%-66.2% to 35.5%-64.5%; specificity ranging from 97.6% [95% CI, 95.6%-98.9%] to 97.9% [95% CI, 95.6%-99.2%]). Luminal subtypes showed substantial misclassification using ER, PR, and ERBB2 status alone. Incorporation of Ki-67 (≥20%) or histologic grade improved discrimination between luminal A and luminal B tumors, increasing luminal B classification from 12.2% (95% CI, 8.5%-16.7%) to 41.2% (95% CI, 35.2%-47.4%), even when PR status was excluded from the panel. Findings were independently validated in women with breast cancer from Ghana.
Conclusions and Relevance: In this cross-sectional study of African breast cancer populations, standard IHC markers performed well for basal-like tumors but frequently misclassified luminal subtypes without proliferation markers. When testing was constrained, proliferation markers contributed more to molecular approximation than PR, with histologic grade providing useful information when Ki-67 was unavailable. These findings support tiered, resource-adapted classification where molecular assays are inaccessible.
Related
- Complex sclerosing lesions of the breast mimicking carcinoma: diagnostic pitfalls and the decisive role of immunohistochemistry
- Multimodal assessment of exceptional responders refines subtyping-directed precision treatment in HR+/HER2– breast cancer
- Kinase-based molecular subtyping and a prognostic risk model in colorectal cancer with functional validation of PLK4
- Discovery and Validation of Gut Microbiome Features Associated with Dietary Patterns in U.S. Black/African and Hispanic/Latino Populations
- AI-Guided Histopathological and Molecular Phenotyping of Salivary Glands in Sjögren's Disease: Subtyping, Mechanistic Insights, and Translational Implications-A Systematic Review and Structured Functional Synthesis.
BibTeX
@article{sayed2026immunohistochemistry,
title = {{Immunohistochemistry vs Molecular Breast Cancer Subtyping Among African Populations}},
author = {Shahin Sayed and Li Feng and Hela Koka and Manel Haj Mansour and Difei Wang and Maria Brown and Kristine Jones and Margaret Maina and Veronica Ngundo and Alfred Mburu Githuka and Zaitun Ajuoga and Shaoqi Fan and Amber N. Hurson and Xing Hua and Petra Lenz and Rosemary Wangari Kamau and Beryl Akinyi Ooro and Francis Makokha and Stefan Ambs and Aaron M. Rozeboom and Amy Hutchinson and Belynda Hicks and Mustapha Abubakar and Xiaohong R. Yang},
journal = {JAMA network open},
year = {2026},
month = oct,
doi = {10.1001/jamanetworkopen.2026.38664},
url = {https://europepmc.org/article/PMC/PMC13659570},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Immunohistochemistry vs Molecular Breast Cancer Subtyping Among African Populations
AU - Shahin Sayed
AU - Li Feng
AU - Hela Koka
AU - Manel Haj Mansour
AU - Difei Wang
AU - Maria Brown
AU - Kristine Jones
AU - Margaret Maina
AU - Veronica Ngundo
AU - Alfred Mburu Githuka
AU - Zaitun Ajuoga
AU - Shaoqi Fan
AU - Amber N. Hurson
AU - Xing Hua
AU - Petra Lenz
AU - Rosemary Wangari Kamau
AU - Beryl Akinyi Ooro
AU - Francis Makokha
AU - Stefan Ambs
AU - Aaron M. Rozeboom
AU - Amy Hutchinson
AU - Belynda Hicks
AU - Mustapha Abubakar
AU - Xiaohong R. Yang
PY - 2026
DA - 2026/10/01
JO - JAMA network open
DO - 10.1001/jamanetworkopen.2026.38664
UR - https://europepmc.org/article/PMC/PMC13659570
AB - Importance: Breast cancer subtyping based on immunohistochemistry (IHC) guides systemic therapy where gene expression profiling assays are unavailable, yet its validity against molecular reference standards remains poorly characterized in African populations, where laboratory infrastructure and access to pathology services are limited. Objective: To evaluate concordance between IHC-based breast cancer subtyping and PAM50 intrinsic subtypes in East and West African populations and identify resource-appropriate strategies to improve classification. Design, Setting, and Participants: This cross-sectional study included Kenyan (diagnosed 2012-2022) and Ghanaian women (diagnosed 2013-2015) with invasive breast cancer, from whom formalin-fixed, paraffin-embedded tumor specimens were collected during the same periods. Gene expression profiling and data analyses were performed between April 2020 and August 2026 for both cohorts. Exposures: Tumor subtyping using standard IHC markers (estrogen receptor [ER], progesterone receptor [PR], and ERBB2 status and Ki-67) and histologic grade vs PAM50 intrinsic subtyping derived from a gene expression panel. Main Outcomes and Measures: Concordance between IHC-based and PAM50 intrinsic subtypes was assessed using Cohen κ statistics, with sensitivity and specificity calculated against PAM50. Results: Among 460 women in Kenya with breast cancer (mean [SD] age at diagnosis, 50.3 [12.5] years), 224 (49.4%) had grade 3 disease and 148 (42.3%) had stage III or IV tumors. A total of 451 women in Ghana with breast cancer (mean [SD] age, 49.9 [12.0] years; 317 [75.1%] with grade 3 disease) were enrolled as a validation cohort. PAM50 classified patients’ tumors as luminal A (201 tumors [43.7%]), luminal B (82 tumors [17.8%]), ERBB2 -enriched (50 tumors [10.9%]), basal-like (99 tumors [21.5%]), and normal-like (28 tumors [6.1%]). Concordance between IHC and PAM50 was highest for basal-like tumors (sensitivity ranging from 73.3% [95% CI, 61.9%-82.9%] to 79.6% [95% CI, 70.3%-87.1%]; specificity ranging from 96.9% [95% CI, 93.9%-98.6%] to 97.3% [95% CI, 94.9%-98.7%]) and moderate for ERBB2 -enriched tumors (sensitivity was 50.0% across all schemes, with 95% CIs ranging from 33.8%-66.2% to 35.5%-64.5%; specificity ranging from 97.6% [95% CI, 95.6%-98.9%] to 97.9% [95% CI, 95.6%-99.2%]). Luminal subtypes showed substantial misclassification using ER, PR, and ERBB2 status alone. Incorporation of Ki-67 (≥20%) or histologic grade improved discrimination between luminal A and luminal B tumors, increasing luminal B classification from 12.2% (95% CI, 8.5%-16.7%) to 41.2% (95% CI, 35.2%-47.4%), even when PR status was excluded from the panel. Findings were independently validated in women with breast cancer from Ghana. Conclusions and Relevance: In this cross-sectional study of African breast cancer populations, standard IHC markers performed well for basal-like tumors but frequently misclassified luminal subtypes without proliferation markers. When testing was constrained, proliferation markers contributed more to molecular approximation than PR, with histologic grade providing useful information when Ki-67 was unavailable. These findings support tiered, resource-adapted classification where molecular assays are inaccessible.
SN - 2574-3805
ER -